

NEW THERAPEUTIC APPROACH FOR OSTEOSARCOMA

ANTI-IL34 ANTIBODIES

TECHNOLOGY

IL-34 is as a cytokine promoting osteosarcoma progression by increasing the tissue vasculature, by stimulating the recruitment of macrophages and their differentiation toward M2 phenotype. Consequently, IL-34 appears as a pro-metastatic regulator in osteosarcoma.

IL34 produced by cancer cells is also involved in immunosuppression and chemoresistance.

We have developed an antibody binding IL34 with a high affinity. The IL34 antibody are capable of inhibiting IL34-mediated cell proliferation and intracellular signal transduction

By using a anti-IL34 antibody, we observed a total blockade of tumour progression in a syngenic model of osteosarcoma.

APPLICATIONS

- Osteosarcoma and others cancers (Ewing sarcoma, breast and prostate cancer, lung cancer)

KEY BENEFITS

- Prevention of tumor growth and metastatic
- Possible combination with conventional chemotherapy
- No side effect

INTELLECTUAL PROPERTY

- EP Patent application :
2014EP-0199494
19/12/2014
- Extensions : USA, EP, CA

STAGE OF DEVELOPPEMENT

- Target validation
- In vitro and In vivo validation

LABORATORY

- INSERM UMR1232 Team 9
- Institute of Cancer Research in Western France
- Pr Heymann Dominique

CONTACT

SATT QUEST VALORISATION

Phone +33 (0)2 99 87 56 01
email : info@ouest-valorisation.fr

DV2439